Literature DB >> 34716445

ALS antisense drug falters in phase III.

Asher Mullard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34716445     DOI: 10.1038/d41573-021-00181-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

Review 1.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 2.  Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases.

Authors:  Giulia Gentile; Giovanna Morello; Valentina La Cognata; Maria Guarnaccia; Francesca Luisa Conforti; Sebastiano Cavallaro
Journal:  J Pers Med       Date:  2022-05-10

3.  Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis.

Authors:  Claudia Albertini; Alessandra Salerno; Silvia Atzeni; Elisa Uliassi; Francesca Massenzio; Annalisa Maruca; Roberta Rocca; Marko Mecava; Filomena S G Silva; Débora Mena; Pedro Valente; Ana I Duarte; Daniel Chavarria; Maicol Bissaro; Stefano Moro; Stephanie Federico; Giampiero Spalluto; Ondřej Soukup; Fernanda Borges; Stefano Alcaro; Barbara Monti; Paulo J Oliveira; Josè C Menéndez; Maria Laura Bolognesi
Journal:  ACS Chem Neurosci       Date:  2022-07-22       Impact factor: 5.780

Review 4.  Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?

Authors:  Hugo Alarcan; Yara Al Ojaimi; Debora Lanznaster; Jean-Michel Escoffre; Philippe Corcia; Patrick Vourc'h; Christian R Andres; Charlotte Veyrat-Durebex; Hélène Blasco
Journal:  J Pers Med       Date:  2022-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.